Home|Journals|Articles by Year|Audio Abstracts RSS - TOC


Khalid Mohammed Alabdulwahhab.


From Editor’s Desk…

While booster shots of COVID-19 vaccinations are widely used in a number of nations, the omicron form is getting prominence in a few countries. Vaccination studies conducted recently found extremely high initial levels of protection against death, serious sickness, and all symptomatic infection. Regrettably, it appears as though the battle is not yet over, as specialists fear that a new Covid type, potentially even more dangerous than the already prevalent Omicron variant, could hit the planet within the next two years.

According to reports, there is still a long way to go until the globe is completely free of COVID-19, which will exist in forever and will always pose a death danger similar to flu. Delta+ Omicron recombinant virus is a fusion of the coronavirus types Delta and Omicron. Recombinants were expected due to the rapid spread of both Omicron and Delta COVID types, the World Health Organization (WHO) declared recently in response to the identification of the first substantial evidence of a hybrid virus (Omicron and Delta).

Numerous research investigating new variations are now being conducted. However, there have been no modifications in the disease’s severity or transmissibility observed to date. While many nations have discontinued required testing and sequencing, the WHO emphasizes the need of sequencing, claiming that it will give crucial data for pandemic control efficiently.

The new variety may evolve at the same rate as the types that are already spreading. However, the crucial question is how far vaccination can safeguard the community. Subsequent versions will surely put the efficiency of the immune system to the test.

Dr. Khaid Mohammed Alabdulwahhab
Editor in Chief

Key words: Editorial

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.